IL-12

October 4, 2017

Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients

News

All ovarian cancer patients treated in the Phase 1b OVATION trial benefited from the combination of Celsion‘s GEN-1 with standard of care. The trial enrolled advanced ovarian cancer patients who ... Read more

August 30, 2017

Celsion to Present New Data from OVATION Trial at Ovarian Cancer Meeting

News

All newly diagnosed ovarian cancer patients enrolled in the OVATION Phase 1b trial (NCT02480374) to date benefited from the addition of GEN-1 to standard of care, according to Celsion, the drug’s developer. ... Read more

January 23, 2017January 24, 2017

GEN-1 Immunotherapy Continues to Show Promise in Newly Diagnosed Advanced Ovarian Cancer Patients

News

Combining the DNA-based immunotherapy GEN-1 with standard of care neoadjuvant chemotherapy continues to show promise in patients with newly-diagnosed advanced ovarian cancer who will undergo interval debulking surgery, according to ... Read more

December 19, 2016

Celsion Enrolling Patients to Complete Phase 1 OVATION Clinical Trial

News

The independent Data Safety Monitoring Board has completed its safety review of data from the first four groups of the ongoing Phase 1 OVATION Study. As a result, Celsion Corporation ... Read more

November 14, 2016

GEN-1 Immunotherapy Holds Promise for Newly Diagnosed Advanced Ovarian Cancer Patients, Study Says

News

Combining the DNA-based immunotherapy GEN-1 with neoadjuvant standard-of-care chemotherapy to treat newly-diagnosed advanced ovarian cancer patients who will undergo interval debulking surgery seems to be a promising therapeutic approach, according to ... Read more